8-K: Edwards Lifesciences Reports Strong Q4, Raises 2026 Outlook

Edwards Lifesciences delivered robust fourth-quarter 2025 results, driven by strong TAVR and TMTT sales, and increased its full-year 2026 financial guidance.

Summary

• Fourth quarter 2025 sales grew 13.3% to $1.57 billion, or 11.6% on a constant currency basis.
• Full-year 2025 sales increased 11.5% to $6.07 billion, or 10.7% on a constant currency basis.
• Q4 Transcatheter Aortic Valve Replacement (TAVR) sales grew 12.0% to $1.16 billion, or 10.6% on a constant currency basis.
• Q4 Transcatheter Mitral and Tricuspid Therapies (TMTT) sales grew more than 40% to $156 million.
• Q4 GAAP diluted EPS was $0.11; adjusted diluted EPS was $0.58.
• Increased confidence in FY 2026 constant currency sales growth of 8-10% and adjusted EPS of $2.90-$3.05.
• FY 2026 revenue outlook for TMTT includes growth of 35-45% to $740-$780 million.
• FDA approved SAPIEN M3, the first transcatheter mitral replacement therapy in the U.S.
• Long-term clinical data from PARTNER 3 (7-year) and PARTNER 2 (10-year) trials reinforced the durability and performance of the SAPIEN platform.
• The U.S. Centers for Medicare and Medicaid Services (CMS) formally opened the process to reconsider the National Coverage Determination for TAVR.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive report, driven by strong sales growth across key segments, increased future guidance, and significant product approvals and clinical data reinforcing market leadership, despite some non-recurring charges impacting GAAP EPS.

Positives

• Strong Q4 2025 sales growth of 13.3% to $1.57 billion, demonstrating robust market demand.
• Exceptional TMTT sales growth of over 40% in Q4 to $156 million, driven by global adoption of PASCAL and EVOQUE.
• Increased confidence in FY 2026 constant currency sales growth guidance of 8-10% and adjusted EPS guidance of $2.90-$3.05, indicating an improved outlook.
• FDA approval of SAPIEN M3 expands the mitral portfolio in the U.S. as the first transcatheter replacement option for mitral disease patients.
• Positive long-term clinical data from PARTNER 3 (7-year) and PARTNER 2 (10-year) trials reinforce the SAPIEN platform's durability and set a new clinical standard.
• CMS initiated reconsideration of the TAVR National Coverage Determination, which has the potential to improve timely and equitable patient access.
• Modest year-over-year share improvement in the European TAVR market following a competitor's exit.
• Updated European guidelines are reshaping clinical discussions and reinforcing TAVR's role for a broader patient population.
• Continued adoption of RESILIA therapies drove 4% growth (2% constant currency) in the Surgical segment.
• Plans for a preliminary introduction of a new surgical Left Atrial Appendage Closure (LAAC) technology later in 2026.

Negatives

• Q4 GAAP diluted EPS was significantly lower at $0.11 compared to adjusted EPS of $0.58, primarily due to substantial litigation expenses and impairment losses.
• Gross profit margin slightly decreased to 78.1% (78.3% adjusted) in Q4 2025 from 78.9% (79.0% adjusted) in Q4 2024.
• Selling, general, and administrative expenses increased to 38.4% of sales in Q4 2025 from 35.5% in Q4 2024, partly due to strategic investments delayed from previous quarters.
• Q4 2025 GAAP operating profit margin was 9.6%, significantly lower than the 22.6% reported in Q4 2024.
• The effective tax rate for Q4 2025 was higher than expected at 29.0%, compared to 11.6% in Q4 2024.
• Incurred a loss on impairment of $99.8 million ($76.5 million net of tax) in Q4 2025 related to an investment in JenaValve Technologies.
• Reported $208.6 million in 'Certain Litigation Expenses' in Q4 2025, a substantial increase from $12.6 million in Q4 2024.

Risks

• Risks and uncertainties that could cause actual results or experience to differ materially from forward-looking statements, as detailed in the company's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024.
• A loss on impairment of $99.8 million related to the investment in JenaValve Technologies indicates potential challenges or underperformance in certain strategic investments.
• Significant 'Certain Litigation Expenses' totaling $208.6 million in Q4 2025 highlight ongoing legal and intellectual property risks that can materially impact financial results.

Future Outlook

Edwards Lifesciences has increased confidence in achieving its 2026 sales growth rate guidance of 8-10% (constant currency) and adjusted EPS guidance of $2.90-$3.05. The company anticipates TMTT sales to grow 35-45% to $740-$780 million in 2026. Key catalysts for future growth include distinguished long-term clinical trial results (PARTNER 3 7-year, PARTNER 2 10-year), the impact of the practice-changing EARLY TAVR trial, new European guidelines for treating aortic stenosis patients, and approvals of the first transcatheter mitral replacement therapy. Additional meaningful catalysts expected later in 2026 include next-generation TEER, PASCAL for U.S. tricuspid patients, continued scaling of EVOQUE, and the potential of increased patient access from an updated TAVR NCD. The company also plans a preliminary introduction of a new surgical Left Atrial Appendage Closure (LAAC) technology later in 2026.

Management Comments

• "Edwards strong fourth quarter and full year performance in 2025 reflect our differentiated strategy with a clear vision around three key elements: focusing solely on structural heart, solving large, urgent and very complex patient needs, and pursuing unique opportunities to innovate and lead, all achieved through excellent execution by our deeply experienced teams." Bernard Zovighian, Edwards CEO.
• "Based on multiple catalysts and the company's strong fourth quarter performance, we have increased confidence in our outlook for 2026 and believe that our 70 years of expertise in valve innovation and world-class evidence will create sustainable growth and expanded profitability." Bernard Zovighian, Edwards CEO.
• "These enduring catalysts benefitting Edwards in 2026 and the years ahead include distinguished long-term results unique to Edwards from the PARTNER 3 7-year and PARTNER 2 10-year trials, the impact of the practice-changing EARLY TAVR trial, new guidelines for treating aortic stenosis patients in Europe and the approvals of the first transcatheter mitral replacement therapy." Bernard Zovighian, Edwards CEO.
• "We expect additional meaningful catalysts later in 2026 to fuel sustainable growth into the future, including next-generation TEER, PASCAL for U.S. tricuspid patients, continued scaling of EVOQUE and the potential of increased patient access from an updated TAVR NCD." Bernard Zovighian, Edwards CEO.

Industry Context

StockSavvy.ai notes that Edwards Lifesciences' strong performance in structural heart, particularly TAVR and TMTT, aligns with the growing global demand for minimally invasive cardiac interventions driven by an aging population and increasing prevalence of heart valve diseases. The company's focus on innovation and world-class clinical evidence, such as the PARTNER trials and EARLY TAVR, positions it well against competitors in a market increasingly valuing long-term durability and patient outcomes. The FDA approval of SAPIEN M3 and the CMS reconsideration of TAVR NCD indicate a supportive regulatory environment for expanding patient access to advanced therapies.

Comparison to Industry Standards

• Edwards' SAPIEN platform, with 7-year PARTNER 3 and 10-year PARTNER 2 data, sets a new clinical standard for safety, efficacy, durability, and lifetime management of patients in transcatheter heart valve therapy, distinguishing it from competitors.
• The company's TAVR procedural growth was comparable across the U.S. and OUS, and average price and competitive position were stable globally, suggesting strong market positioning relative to peers.
• The modest year-over-year share improvement in Europe for TAVR is directly attributed to a competitor's exit, indicating market share gains in a competitive landscape.
• The FDA approval of SAPIEN M3 as the first transcatheter mitral replacement option in the U.S. positions Edwards as a leader in addressing the globally underserved population with mitral disease, potentially outpacing competitors in this emerging segment.

Legal Proceedings

• Incurred $208.6 million in 'Certain Litigation Expenses' in Q4 2025, related to intellectual property litigation, settlements, contingencies, and external legal costs.
• Full-year 2025 'Certain Litigation Expenses' totaled $325.4 million.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased guidance, and strategic product advancements, potentially leading to increased share value.
• Patients: Improved access to life-saving therapies (TAVR, TMTT) through new product approvals (SAPIEN M3), expanded clinical evidence, and potential changes in coverage determinations (TAVR NCD).
• Physicians/Healthcare Providers: Enhanced confidence in Edwards' therapies due to long-term clinical data, expanded product portfolio, and ongoing training initiatives.
• Employees: Continued focus on innovation and execution, potentially leading to stable or growing employment opportunities within a leading structural heart company.
• Creditors: Strong cash position ($3.0 billion) and manageable debt ($600 million) indicate solid financial health.

Next Steps

• Continue expanding the number of centers and physician training for TMTT therapies (PASCAL, EVOQUE, SAPIEN M3).
• Strategic introduction of SAPIEN M3, initially leveraging sites from the ENCIRCLE pivotal clinical trial.
• Preliminary introduction of a new surgical Left Atrial Appendage Closure (LAAC) technology later in 2026.
• Monitor the CMS reconsideration process for the TAVR National Coverage Determination for potential increased patient access.
• Anticipate additional meaningful catalysts later in 2026, including next-generation TEER, PASCAL for U.S. tricuspid patients, continued scaling of EVOQUE, and potential increased patient access from an updated TAVR NCD.

Key Dates

Recommendation

The company delivered robust Q4 and full-year 2025 results, exceeding expectations with strong growth in key structural heart segments (TAVR and TMTT). The increased 2026 guidance for both sales and adjusted EPS, coupled with significant product approvals like SAPIEN M3 and compelling long-term clinical data, reinforces Edwards Lifesciences' market leadership and innovation pipeline. While GAAP EPS was impacted by non-recurring litigation and impairment charges, the underlying operational performance and future outlook are exceptionally strong, making it a compelling investment.

Keywords

Edwards Lifesciences, EW, TAVR, TMTT, Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, SAPIEN, SAPIEN M3, PASCAL, EVOQUE, RESILIA, structural heart, medical devices, heart valve disease, financial results, Q4 2025, 2026 outlook, FDA approval, clinical trials, PARTNER 3, PARTNER 2, EARLY TAVR, NCD, CMS, surgical heart